12 December 2017Americas
Gilead follows Kite acquisition with $567m buy
Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
29 August 2017 Gilead Sciences is to acquire Kite Pharma for $11.9 billion, after the deal was unanimously approved by both companies’ boards of directors.
Americas
26 February 2018 Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.
Editor's picks
Editor's picks
Americas
29 August 2017 Gilead Sciences is to acquire Kite Pharma for $11.9 billion, after the deal was unanimously approved by both companies’ boards of directors.
Americas
26 February 2018 Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.
Americas
29 August 2017 Gilead Sciences is to acquire Kite Pharma for $11.9 billion, after the deal was unanimously approved by both companies’ boards of directors.
Americas
26 February 2018 Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.